首页 | 本学科首页   官方微博 | 高级检索  
     

稳心颗粒对异丙肾上腺素诱导心功能不全大鼠的影响
引用本文:周奋,胡申江 牟芸. 稳心颗粒对异丙肾上腺素诱导心功能不全大鼠的影响[J]. 中国中药杂志, 2007, 32(16): 1676-1679
作者姓名:周奋  胡申江 牟芸
作者单位:浙江大学,医学院,附属第一医院,浙江,杭州,310003
摘    要:目的:研究稳心颗粒对异丙肾上腺素(soproterenol,ISO)诱导慢性心功能不全大鼠血流动力学和乌头碱致心律失常的影响。方法:大鼠随机分为6组,正常组:给予蒸馏水灌胃;阳性药(代文30 mg·kg-1)+正常组;稳心颗粒(9 g·kg-1)+正常组;ISO(85 mg·kg-1)组造模2周后给予蒸馏水灌胃;稳心颗粒(9 g·kg-1)+ISO组;代文(30 mg·kg-1)+ISO组。分别在给药后第4,10周,各组大鼠进行心脏超声检查,同时在第10周进行血流动力学检测,并观察各组大鼠对乌头碱致心律失常的反应。结果:心超提示:ISO组左室舒张末期直径(LVIDd)、左室收缩末期直径(LVIDs)、左室短轴缩短率(FS)、射血分数(EF)较正常组均显著下降(P <0.05),服用代文4周后左室收缩末期直径(LVIDs)明显缩短(P<0.01),FS,EF明显改善(P<0.01),给予代文10周后LVIDd,LVIDs,FS,EF仍持续改善(P<0.01);给予稳心颗粒4周和10周后心超指标LVIDs,LVIDd,FS,EF均无明显改善。血流动力学检测结果提示:与正常组相比,ISO组LVSP,±dp/dtmax均明显下降(P<0.01,P<0.05),LVEDP显著升高(P<0.01),HR无明显改变;给予代文10周后LVSP,LVEDP,±dp/dtmax较ISO组明显改善(P<0.05);稳心颗粒10周后与ISO组相比,LVEDP较ISO组明显降低(P<0.05),±dp/dtmax较ISO组明显改善(P<0.05)。在乌头碱所致心律失常的试验中发现,与正常组相比,ISO组室性心律失常的持续时间明显延长,服用稳心颗粒后室性心律失常的持续时间缩短P<0.05);服用代文后室性心律失常持续时间无明显改善。结论:稳心颗粒可一定程度地改善异丙肾上腺素诱导大鼠的慢性心功能不全;稳心颗粒对乌头碱所致的大鼠心律失常具有保护作用。

关 键 词:稳心颗粒  异丙肾上腺素  心力衰竭  血流动力学  心律失常  乌头碱
文章编号:1001-5302(2007)16-1676-04
收稿时间:2006-06-15
修稿时间:2006-06-15

Protection effect of Wenxin Keli on isoproterenol induced heart failure in rats
ZHOU Fen; HU Shen-jiang; MU Yun. Protection effect of Wenxin Keli on isoproterenol induced heart failure in rats[J]. China Journal of Chinese Materia Medica, 2007, 32(16): 1676-1679
Authors:ZHOU Fen   HU Shen-jiang   MU Yun
Affiliation:Department of Cardiology, First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
Abstract:Objective: To study the treatment effect of Wenxin Keli on isoproterenol (ISO) induced heart failure in rats. Method: Sixty six-week old male Wistar rats were randomized into six groups. The rats in control group were only receive distilled water every day.The rats in ISO group also received two subcutaneous injections (85 mg·kg-1) of ISO, which were separated by a 24 hour interval and began to receive distilled water 2 weeks later every day.The rats in Wenxin Keli and control group were receive Wenxin Keli (9 mg·kg-1) every day.The rats in Wenxin Keli and ISO group received two subcutaneous injections (85 mg·kg-1) of ISO, which were separated by a 24 hour interval and began to receive Wenxin Keli (9 mg·kg-1) 2 weeks later every day.The rats in valsartan and control group were receive valsartan every day.The rats in valsartan and ISO group received two subcutaneous injections (85 mg·kg-1) of ISO, which were separated by a 24 hour interval and began to receive valsartan 30 mg·kg-1 2 weeks later every day. Echocardiogram measurement in rats were carried out after 4 weeks and 10 weeks feeding medince of hemodynamic measurement and aconitine induced arrhythmia in rats were carried out after 10 weeks. Result: Echocardiogram indicated that left ventricular internal diameter at diastolic phase (LVIDd), left ventricular internal diameter at systolic phase (LVIDs), LV percent fractional shortening (FS) and LV ejection fraction (EF) were decreased in the ISO group. Treatment with valsartan 4 weeks later, FS and EF were increased compared with the ISO group and 10 weeks later, LVIDd, LVIDs, FS, EF were increased. However,treatment with Wenxin Keli 10 weeks later, LVIDs, FS, EF were not changed obviously. Hemodynamic measurement showed that left ventricular end diastolic pressure (LVEDP), left ventricular systolic pressure (LVSP), and dp/dtmax were improved after 10 weeks of treatment with valsartan. The LVEDP was decreased and dp/dtmax was increased after 10 weeks of treatment with Wenxin Keli. Aconitine induced arrhythmia in rats in Wenxin Keli and control group were less serious than those in control group, aconitine induced arrhythmia in rats in Wenxin Keli and ISO group were less serious than those in ISO group. conclusion: Wenxin Keli could greatly improve the ISO induced cardiac dysfunction and protect the aconitine-induced arrhythmia in rats.
Keywords:Wenxin Keli   isoproterenol   heart failure   hemodynamics   arrhythmia   aconitine
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号